An aerosol formulation of R-salbutamol sulfate for pulmonary inhalation
An aerosol formulation containing 7.5 mg of R-salbutamol sulfate was developed. The aerosol was nebulized with an air-jet nebulizer, and further assessed according to the new European Medicines Agency (EMA) guidelines. A breath simulator was used for studies of delivery rate and total amount of the...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2014-02-01
|
Series: | Acta Pharmaceutica Sinica B |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383513001159 |
id |
doaj-7aa1a841ba1f4af48ba8e3d7231297d3 |
---|---|
record_format |
Article |
spelling |
doaj-7aa1a841ba1f4af48ba8e3d7231297d32020-11-25T01:01:06ZengElsevierActa Pharmaceutica Sinica B2211-38352211-38432014-02-0141798510.1016/j.apsb.2013.12.010An aerosol formulation of R-salbutamol sulfate for pulmonary inhalationXuemei Zhang0Qing Liu1Junhua Hu2Ling Xu3Wen Tan4School of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, ChinaSchool of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, ChinaSchool of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, ChinaKey-Pharma Biomedical Inc., Dongguan 523000, ChinaSchool of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, ChinaAn aerosol formulation containing 7.5 mg of R-salbutamol sulfate was developed. The aerosol was nebulized with an air-jet nebulizer, and further assessed according to the new European Medicines Agency (EMA) guidelines. A breath simulator was used for studies of delivery rate and total amount of the active ingredient at volume of 3 mL. A next generation impactor (NGI) with a cooler was used for analysis of the particle size and in vitro lung deposition rate of the active ingredient at 5 °C. The anti-asthmatic efficacy of the aerosol formulation was assessed in guinea pigs with asthma evoked by intravenous injection of histamine compared with racemic salbutamol. Our results show that this aerosol formulation of R-salbutamol sulfate met all the requirements of the new EMA guidelines for nebulizer. The efficacy of a half-dose of R-salbutamol equaled that of a normal dose of racemic salbutamol.http://www.sciencedirect.com/science/article/pii/S2211383513001159R-salbutamolNebulizerNGIParticle sizeDose uniformityGuinea pigsAsthma |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xuemei Zhang Qing Liu Junhua Hu Ling Xu Wen Tan |
spellingShingle |
Xuemei Zhang Qing Liu Junhua Hu Ling Xu Wen Tan An aerosol formulation of R-salbutamol sulfate for pulmonary inhalation Acta Pharmaceutica Sinica B R-salbutamol Nebulizer NGI Particle size Dose uniformity Guinea pigs Asthma |
author_facet |
Xuemei Zhang Qing Liu Junhua Hu Ling Xu Wen Tan |
author_sort |
Xuemei Zhang |
title |
An aerosol formulation of R-salbutamol sulfate for pulmonary inhalation |
title_short |
An aerosol formulation of R-salbutamol sulfate for pulmonary inhalation |
title_full |
An aerosol formulation of R-salbutamol sulfate for pulmonary inhalation |
title_fullStr |
An aerosol formulation of R-salbutamol sulfate for pulmonary inhalation |
title_full_unstemmed |
An aerosol formulation of R-salbutamol sulfate for pulmonary inhalation |
title_sort |
aerosol formulation of r-salbutamol sulfate for pulmonary inhalation |
publisher |
Elsevier |
series |
Acta Pharmaceutica Sinica B |
issn |
2211-3835 2211-3843 |
publishDate |
2014-02-01 |
description |
An aerosol formulation containing 7.5 mg of R-salbutamol sulfate was developed. The aerosol was nebulized with an air-jet nebulizer, and further assessed according to the new European Medicines Agency (EMA) guidelines. A breath simulator was used for studies of delivery rate and total amount of the active ingredient at volume of 3 mL. A next generation impactor (NGI) with a cooler was used for analysis of the particle size and in vitro lung deposition rate of the active ingredient at 5 °C. The anti-asthmatic efficacy of the aerosol formulation was assessed in guinea pigs with asthma evoked by intravenous injection of histamine compared with racemic salbutamol. Our results show that this aerosol formulation of R-salbutamol sulfate met all the requirements of the new EMA guidelines for nebulizer. The efficacy of a half-dose of R-salbutamol equaled that of a normal dose of racemic salbutamol. |
topic |
R-salbutamol Nebulizer NGI Particle size Dose uniformity Guinea pigs Asthma |
url |
http://www.sciencedirect.com/science/article/pii/S2211383513001159 |
work_keys_str_mv |
AT xuemeizhang anaerosolformulationofrsalbutamolsulfateforpulmonaryinhalation AT qingliu anaerosolformulationofrsalbutamolsulfateforpulmonaryinhalation AT junhuahu anaerosolformulationofrsalbutamolsulfateforpulmonaryinhalation AT lingxu anaerosolformulationofrsalbutamolsulfateforpulmonaryinhalation AT wentan anaerosolformulationofrsalbutamolsulfateforpulmonaryinhalation AT xuemeizhang aerosolformulationofrsalbutamolsulfateforpulmonaryinhalation AT qingliu aerosolformulationofrsalbutamolsulfateforpulmonaryinhalation AT junhuahu aerosolformulationofrsalbutamolsulfateforpulmonaryinhalation AT lingxu aerosolformulationofrsalbutamolsulfateforpulmonaryinhalation AT wentan aerosolformulationofrsalbutamolsulfateforpulmonaryinhalation |
_version_ |
1725210839840980992 |